Phase 2Recruiting
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)
- Sponsor
- University of North Carolina, Chapel Hill (Academic or other)
- Enrollment
- 52 planned
- Conditions
- EoE; Eosinophilic Esophagitis; Eosinophilic Esophagitis (EoE)
- Interventions
- Upadacitinib 30mg Dose; Upadacitinib Matching Placebo
- Ages
- adults, older adults
- Registry
- NCT07588568
Full record on ClinicalTrials.gov
From the registry
The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests
Primary outcomes
- Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatment
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered